PMID: 2174412Dec 15, 1990Paper

Loss of MHC class-I expression in cervical carcinomas

International Journal of Cancer. Journal International Du Cancer
M E Connor, P L Stern

Abstract

The expression of MHC class-I antigens was analysed in 67 cervical carcinoma biopsies; 16% of the biopsies showed complete or heterogeneous loss of HLA expression as judged by reactivity with antibodies recognizing monomorphic determinants of the class-I heavy chain bound to beta 2 microglobulin (beta 2m). In addition, other biopsies showed a loss in expression of particular allelic products: 23% for HLA-A2; 17% for HLA-A3; 23% for HLA-Bw4 and 19% for HLA-Bw6. Three biopsies showed changes at 2 alleles, 2 of which were at both HLA-A and -B loci. Down-regulation of class-I expression may be virally mediated and HPV DNA is frequently found in cervical carcinomas. However, there appeared to be no direct correlation between the detection of HPV 16 or 18 DNA in these tumours and changes in HLA expression. There was also no correlation with the expression of the oncofoetal antigen 5T4. Our results show that a significant proportion (at least 30%) of the cervical carcinomas showed some alteration in MHC class-I expression. Such changes may allow tumours to evade immune surveillance with more rapid progression. There was, however, no correlation with tumour type, degree of differentiation or stage of disease at presentation.

References

Jan 15, 1990·International Journal of Cancer. Journal International Du Cancer·N Hole, P L Stern
Jan 1, 1990·British Journal of Cancer·P J SouthallP L Stern
Jan 1, 1990·British Journal of Cancer·H JonesP Stern
Feb 15, 1986·International Journal of Cancer. Journal International Du Cancer·F MomburgP Möller
Jan 1, 1989·The Journal of Experimental Medicine·F Momburg, S Koch
Sep 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·P G NataliC Russo
Aug 1, 1989·British Journal of Obstetrics and Gynaecology·J H Shepherd
Dec 15, 1987·International Journal of Cancer. Journal International Du Cancer·D Di LucaE Cassai
Mar 1, 1988·Gynecologic Oncology·W BarnesW D Lancaster
Apr 1, 1988·British Journal of Cancer·R C ReesG Jacob
Jan 1, 1987·British Medical Bulletin·H Festenstein
Mar 1, 1988·British Journal of Cancer·N Hole, P L Stern
Jun 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·M DürstH zur Hausen
Nov 15, 1983·International Journal of Cancer. Journal International Du Cancer·S E KabawatA K Bhan
Jul 1, 1981·Journal of Clinical Pathology·K A FlemingJ O McGee

❮ Previous
Next ❯

Citations

Nov 27, 1996·International Journal of Cancer. Journal International Du Cancer·D P SingalX Qiu
Mar 1, 1996·Cancer Metastasis Reviews·B M Steinberg, T P DiLorenzo
Aug 4, 2010·Archivum Immunologiae Et Therapiae Experimentalis·Akshata Udyavar, Terrence L Geiger
Jun 1, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Sytse J Piersma
Nov 1, 1995·Obstetrics and Gynecology·J F HinesA B Jenson
Oct 1, 1993·Immunology Today·F GarridoP L Stern
Jan 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B PasslickJ R Izbicki
May 17, 2005·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Bor-Ching SheuSu-Ming Hsu
Feb 27, 2004·Gynecologic Oncology·Nina L Fowler, Ian H Frazer
Feb 26, 2000·Veterinary Immunology and Immunopathology·P K Nicholls, M A Stanley
Nov 26, 2002·Virus Research·Margaret A Stanley
Sep 11, 1998·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·T YanoY Ichinose
Mar 1, 1997·Clinics in Dermatology·J MalejczykS Jabłońska
Nov 1, 1996·Immunotechnology : an International Journal of Immunological Engineering·M E RessingC J Melief
Nov 1, 1995·The Journal of Experimental Medicine·T C WuD M Pardoll
Jun 1, 1996·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·I Arany, S K Tyring
Jun 23, 2000·Clinical Obstetrics and Gynecology·R H KaufmanV Vonka
Apr 17, 2004·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M A van EijkerenH J Geuze
Sep 21, 2004·Journal of Gastroenterology and Hepatology·Keishi FujiwaraYasushi Shiratori
Feb 12, 1998·American Journal of Reproductive Immunology : AJRI·C A Mullen
Nov 1, 1992·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·M LehtinenJ Paavonen
Aug 1, 1996·European Journal of Immunogenetics : Official Journal of the British Society for Histocompatibility and Immunogenetics·M F Duggan-KeenP L Stern
Mar 2, 1996·BMJ : British Medical Journal·J F HinesA B Jenson
Jun 1, 1995·Journal of Clinical Pathology·J C RockettA G Morris
Jun 20, 1998·Sexually Transmitted Infections·S A Southern, C S Herrington
Nov 30, 2013·Disease Markers·Camilla NatterChristoph Grimm
Jan 22, 2014·Current Oncology Reports·Tim EisenRobert Hawkins
Jun 1, 1996·Lancet·D A Galloway

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.